NO964431L - Ikke-spleisende varianter av gp350/220 - Google Patents

Ikke-spleisende varianter av gp350/220

Info

Publication number
NO964431L
NO964431L NO964431A NO964431A NO964431L NO 964431 L NO964431 L NO 964431L NO 964431 A NO964431 A NO 964431A NO 964431 A NO964431 A NO 964431A NO 964431 L NO964431 L NO 964431L
Authority
NO
Norway
Prior art keywords
protein
splicing variants
sequences
vectors
proteins
Prior art date
Application number
NO964431A
Other languages
English (en)
Other versions
NO319382B1 (no
NO964431D0 (no
Inventor
Richard Spaete
Winthrop T Jackman
Original Assignee
Aviron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aviron Inc filed Critical Aviron Inc
Publication of NO964431D0 publication Critical patent/NO964431D0/no
Publication of NO964431L publication Critical patent/NO964431L/no
Publication of NO319382B1 publication Critical patent/NO319382B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Fats And Perfumes (AREA)
  • Polarising Elements (AREA)
NO19964431A 1994-04-18 1996-10-18 Isolert DNA-fragment som koder for EBV gp350-proteinet eller en forkortet versjon av dette, samt vektor, vertcelle og farmasoytisk sammensetning inneholdende DNA-fragmentet eller proteinet og fremgangsmate for fremstilling og anvendelse av disse NO319382B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22929194A 1994-04-18 1994-04-18
PCT/US1995/004611 WO1995028488A1 (en) 1994-04-18 1995-04-13 NON-SPLICING VARIANTS OF gp350/220

Publications (3)

Publication Number Publication Date
NO964431D0 NO964431D0 (no) 1996-10-18
NO964431L true NO964431L (no) 1996-12-11
NO319382B1 NO319382B1 (no) 2005-07-25

Family

ID=22860582

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19964431A NO319382B1 (no) 1994-04-18 1996-10-18 Isolert DNA-fragment som koder for EBV gp350-proteinet eller en forkortet versjon av dette, samt vektor, vertcelle og farmasoytisk sammensetning inneholdende DNA-fragmentet eller proteinet og fremgangsmate for fremstilling og anvendelse av disse

Country Status (25)

Country Link
US (3) US6054130A (no)
EP (1) EP0769056B1 (no)
JP (4) JP3447743B2 (no)
KR (1) KR100380953B1 (no)
CN (2) CN1118573C (no)
AT (1) ATE210184T1 (no)
AU (1) AU707837B2 (no)
BR (1) BR9507473A (no)
CA (1) CA2187908C (no)
CZ (1) CZ292283B6 (no)
DE (1) DE69524415T2 (no)
DK (1) DK0769056T3 (no)
ES (1) ES2170144T3 (no)
FI (2) FI118224B (no)
HU (1) HU221647B1 (no)
LV (1) LV11803B (no)
MY (1) MY114769A (no)
NO (1) NO319382B1 (no)
PL (1) PL181881B1 (no)
PT (1) PT769056E (no)
RU (1) RU2178807C2 (no)
SK (1) SK283446B6 (no)
TW (1) TW496897B (no)
UA (1) UA47403C2 (no)
WO (1) WO1995028488A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
US6692749B1 (en) * 1994-04-18 2004-02-17 Medimmune Vaccines, Inc. Non-splicing variants of gp350/220
AU2582897A (en) * 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
CA2331258C (en) * 1998-06-12 2011-09-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
ITMI20031942A1 (it) * 2003-10-09 2005-04-10 Indena Spa Dna codificante p185^neu e suoi usi terapeutici
ITMI20041965A1 (it) * 2004-10-15 2005-01-15 Augusto Amici "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici"
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2010135514A2 (en) * 2009-05-22 2010-11-25 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, quantitation, isolation and sequencing of cytomegalovirus and epstein-barr virus
US10461635B1 (en) * 2018-05-15 2019-10-29 Analog Devices Global Unlimited Company Low VIN high efficiency chargepump

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069310D1 (en) * 1980-11-03 1984-10-31 Itt Ind Gmbh Deutsche Binary mos ripple carry parallel adder/subtractor and appropriate adding/subtracting stage
US4707358A (en) * 1984-01-30 1987-11-17 The University Of Chicago Vaccine against Epstein-Barr Virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
EP0173254B1 (en) * 1984-08-23 1991-07-24 Hans Joachim Wolf Dna sequences of the ebv genome, recombinant dna molecules, processes for producing ebv-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens
EP0312164A1 (en) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
WO1993019092A1 (fr) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
WO1994020138A1 (en) * 1993-03-12 1994-09-15 Theratech, Inc. Recombinant epstein-barr virus protein and its use in vaccine
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220

Also Published As

Publication number Publication date
EP0769056B1 (en) 2001-12-05
FI964186L (fi) 1996-12-17
SK134396A3 (en) 1997-06-04
FI20075338A7 (fi) 2007-05-10
UA47403C2 (uk) 2002-07-15
EP0769056A4 (en) 1998-03-04
NO319382B1 (no) 2005-07-25
PL316941A1 (en) 1997-02-17
US6054130A (en) 2000-04-25
CN1152940A (zh) 1997-06-25
CN1495262A (zh) 2004-05-12
JPH10501687A (ja) 1998-02-17
LV11803B (en) 1998-01-20
SK283446B6 (sk) 2003-07-01
DE69524415T2 (de) 2002-08-01
US5824508A (en) 1998-10-20
HUT75831A (en) 1997-05-28
LV11803A (lv) 1997-06-20
KR100380953B1 (ko) 2003-10-10
AU2383895A (en) 1995-11-10
US6458364B1 (en) 2002-10-01
FI118224B (fi) 2007-08-31
JP3447743B2 (ja) 2003-09-16
CZ292283B6 (cs) 2003-08-13
FI20075338L (fi) 2007-05-10
PT769056E (pt) 2002-05-31
JP4317786B2 (ja) 2009-08-19
FI964186A0 (fi) 1996-10-18
CZ305496A3 (en) 1997-10-15
JP2005333990A (ja) 2005-12-08
CN1118573C (zh) 2003-08-20
PL181881B1 (pl) 2001-09-28
NO964431D0 (no) 1996-10-18
HU9602894D0 (en) 1996-12-30
CA2187908A1 (en) 1995-10-26
JP2004290199A (ja) 2004-10-21
BR9507473A (pt) 1997-09-23
ES2170144T3 (es) 2002-08-01
AU707837B2 (en) 1999-07-22
WO1995028488A1 (en) 1995-10-26
EP0769056A1 (en) 1997-04-23
DE69524415D1 (de) 2002-01-17
TW496897B (en) 2002-08-01
RU2178807C2 (ru) 2002-01-27
MY114769A (en) 2003-01-31
HU221647B1 (hu) 2002-12-28
DK0769056T3 (da) 2002-04-02
JP2003230396A (ja) 2003-08-19
CA2187908C (en) 2002-09-17
ATE210184T1 (de) 2001-12-15
CN100415895C (zh) 2008-09-03

Similar Documents

Publication Publication Date Title
CA2263889A1 (en) P-selectin ligand proteins
EP1013760A3 (en) Stable bactericidal/permeabilityincreasing protein products and pharmaceutical compositions containing the same
WO1989009787A3 (en) Osteogenic devices
FI20075338A7 (fi) gp350/220:n ei silmukoivia muutoksia
AU2058888A (en) Variants of bovine pancreatic trypsin inhibitor produced by recombinant DNA technology, process, expression vector and recombinant host therefor and pharmaceutical use thereof
IL115199A (en) Composition comprising a polynucleic acid molecule in a liposome and method using said composition
CA2161808A1 (en) Bmp-11 compositions
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
AU8258591A (en) Human mk gene and protein sequence
WO1995030001A3 (en) Novel p-selectin ligand protein
HU895788D0 (en) Process for producing peptides and medical products containing them
PT1259536E (pt) Métodos de preparação de péptidos
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
AU3595489A (en) Amblyommin, a new active substance for anticoagulant therapy
EP0805204A3 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
AU4034095A (en) Cyclohexapeptides and their mixtures, a process for preparing them, and their use
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
EP0723016A3 (en) Leukocyte activation factor
ATE224403T1 (de) Verwendung von kaseinfragmenten als wachstumerförderer
GB9620144D0 (en) Process for the production of of glumatic acid and the use of protein hydrolysates in this process
CA2247998A1 (en) Fragments of cr1 and their use
HUT37109A (en) Process for the phosphinoylation of amino gropus of amino-acids, peptides and esters thereof
AU690729C (en) Process for the preparation of polycondensates of amino acids and the biodegradable polypeptide hydrolysates thereof, and their use in detergent compositions

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees